Literature DB >> 17616652

Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential.

Roland H Stauber1, Wolf Mann, Shirley K Knauer.   

Abstract

Survivin's proposed dual role as an apoptosis inhibitor and a mitotic effector positioned it in the front line of cancer research. Notably, survivin is detected as a cytoplasmic and nuclear protein in cancer patients, which stimulated numerous studies to investigate and to speculate on the functional and prognostic significance of its dynamic localization. Recent evidence shows that the direct interaction of survivin with the nuclear export receptor Crm1 is critically involved in its intracellular localization and cancer-relevant functions. Here, we review our current understanding of the Crm1/survivin interface and discuss its potential prognostic and therapeutic relevance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616652     DOI: 10.1158/0008-5472.CAN-07-0494

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  101 in total

1.  Ellagic acid coordinately attenuates Wnt/β-catenin and NF-κB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis.

Authors:  Prabukumar Anitha; Ramamurthi Vidya Priyadarsini; Krishnamurthy Kavitha; Paranthaman Thiyagarajan; Siddavaram Nagini
Journal:  Eur J Nutr       Date:  2011-12-11       Impact factor: 5.614

2.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

Review 3.  [Possible molecular mechanisms of spontaneous remission in sudden idiopathic hearing loss].

Authors:  U-R Heinrich; J Brieger; R H Stauber; W J Mann
Journal:  HNO       Date:  2011-11       Impact factor: 1.284

4.  High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer.

Authors:  O P Erpolat; P U Gocun; M Akmansu; E Karakus; G Akyol
Journal:  Strahlenther Onkol       Date:  2012-02-08       Impact factor: 3.621

5.  Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.

Authors:  Juana Serrano-López; Josefina Serrano; Vianihuini Figueroa; Antonio Torres-Gomez; Salvador Tabares; Javier Casaño; Noemi Fernandez-Escalada; Joaquín Sánchez-Garcia
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

6.  Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis.

Authors:  Shunzeng Lv; Ekaterina Turlova; Shigang Zhao; Huihui Kang; Mingzhi Han; Hong-Shuo Sun
Journal:  Tumour Biol       Date:  2013-10-08

Review 7.  Prognostic value of survivin expression in breast cancer patients: a meta-analysis.

Authors:  Jian Song; Hong Su; Yang-Yang Zhou; Liang-Liang Guo
Journal:  Tumour Biol       Date:  2013-05-21

8.  Association of cigarette smoking with the expression of nuclear survivin in pathological Stage IA lung adenocarcinomas.

Authors:  Hiroshi Hirano; Hajime Maeda; Yukiyasu Takeuchi; Yoshiyuki Susaki; Ryoji Kobayashi; Akio Hayashi; Naoko Ose; Yukie Nakazawa; Toshihiko Yamaguchi; Soichiro Yokota; Masahide Mori
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

9.  Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

Authors:  Jie Wang; Ze Lu; Bertrand Z Yeung; M Guillaume Wientjes; David J Cole; Jessie L-S Au
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

Review 10.  Taspase1: a 'misunderstood' protease with translational cancer relevance.

Authors:  D Wünsch; A Hahlbrock; S Jung; T Schirmeister; J van den Boom; O Schilling; S K Knauer; R H Stauber
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.